ProDERM
Trial of Intravenous Immune Globulin in Dermatomyositis
Clinical Question
Is intravenous immune globulin (IVIG) effective and safe for the treatment of active dermatomyositis in adults?
Study Overview
Objective
To evaluate the efficacy and safety of intravenous immune globulin (IVIG) compared with placebo in adults with active dermatomyositis
Study Summary
- IVIG significantly improved the primary endpoint: 79% vs 44% achieved TIS ≥20 at 16 weeks (difference 35 pp; 95% CI 17–53; P<0.001)
- At least moderate improvement (TIS ≥40): 68% vs 33% with IVIG vs placebo
- Major improvement (TIS ≥60): 47% vs 15%
- CDASI improved significantly with IVIG
- CK levels did not differ meaningfully between groups
- 282 treatment-related AEs in IVIG group over 40 weeks; headache (42%), pyrexia (19%), nausea (16%)
- 6 thromboembolic events among IVIG-related serious AEs
- First phase 3 RCT leading to FDA approval of IVIG for dermatomyositis
Intervention
IVIG (Octagam 10%) 2.0 g/kg IV every 4 weeks for 16 weeks (4 infusion cycles) vs placebo IV every 4 weeks; open-label extension with IVIG from weeks 16–40
Patients per Arm
IVIG: 47; Placebo: 48
Bottom Line
IVIG produced significantly higher response rates than placebo in adults with active dermatomyositis: 79% vs 44% achieved at least minimal improvement (TIS ≥20) at 16 weeks (difference 35 pp; P<0.001). Moderate and major improvement rates were also significantly higher with IVIG. This was the first phase 3 RCT of IVIG in dermatomyositis and led to FDA approval of Octagam 10% for this indication. The main safety concern was thromboembolic events (6 cases).
Major Points
- ProDERM was a prospective, phase 3, double-blind, parallel-group, randomized, placebo-controlled trial of 95 adults with active dermatomyositis at 36 European and North American centers, from February 2017 to November 2019.
- Patients had definite or probable dermatomyositis (Bohan and Peter criteria), active disease with muscle weakness (MMT-8 <142 with ≥2 abnormal core measures), and were permitted background glucocorticoids (≤20 mg prednisone/day) and up to 2 immunosuppressants.
- The primary endpoint, TIS (Total Improvement Score) ≥20 at week 16, was achieved by 79% (37/47) in the IVIG group vs 44% (21/48) in placebo (difference 35 pp; 95% CI 17–53; P<0.001).
- Secondary endpoints consistently favored IVIG: moderate improvement (TIS ≥40) 68% vs 33%, major improvement (TIS ≥60) 47% vs 15%, and significant CDASI (skin disease) improvement.
- CK levels did not differ meaningfully between groups, suggesting IVIG's benefit in dermatomyositis is more related to immunomodulation affecting muscle inflammation and skin disease than CK normalization.
- Over 40 weeks, 282 treatment-related AEs occurred in the IVIG group. Most common: headache (42%), pyrexia (19%), nausea (16%).
- Six thromboembolic events occurred among 9 serious IVIG-related AEs, highlighting the known prothrombotic risk of high-dose IVIG and the importance of patient screening and monitoring.
- This was the pivotal trial for FDA approval of IVIG (Octagam 10%) for dermatomyositis in July 2021, providing the first Level 1 evidence for a therapy that had been used off-label for decades.
Design
Study Type: Prospective, phase 3, double-blind, parallel-group, randomized, placebo-controlled trial; 1:1 randomization; 16-week randomized phase + 24-week open-label extension; stratified by PhGA disease-activity score
Randomization: 1
Blinding: Double-blind
Centers: 0
Countries:
Sample Size: 95
Arms
| Field | Experimental | Control |
|---|---|---|
| Intervention | IVIG (Octagam 10%) 2.0 g/kg IV every 4 weeks for 16 weeks (4 cycles), infused over 2–5 consecutive days per cycle | Matching placebo IV every 4 weeks on same schedule |
| Duration |
Outcomes
| Outcome | Type | Control | Intervention | HR / OR / RR | P-value |
|---|---|---|---|---|---|
| TIS ≥20 (at least minimal improvement) at week 16: 79% (37/47) vs 44% (21/48); difference 35 pp (95% CI 17–53); P<0.001 | Primary | P<0.001 | |||
| At least moderate improvement (TIS ≥40): 68% vs 33% | Secondary | ||||
| Major improvement (TIS ≥60): 47% vs 15% | Secondary | ||||
| CDASI total activity score: significant improvement with IVIG | Secondary | ||||
| CK level change: no significant difference | Secondary | ||||
| Quality of life (SF-36): improved with IVIG at week 16 | Secondary | ||||
| Serious AEs: 9 IVIG-related (including 6 thromboembolic events) | Secondary | ||||
| Not reported | Adverse | No adverse event data extracted for this trial | |||
Funding
Octapharma Pharmazeutika
Based on: ProDERM (New England Journal of Medicine, 2022)
Authors: R. Aggarwal, C. Charles-Schoeman, J. Schessl, ..., for the ProDERM Trial Group
Citation: N Engl J Med 2022;387:1264-78
Content summarized and formatted by NeuroTrials.ai.